FDA Clears IND Application for InnoCare’s TYK2 Inhibitor
The U.S. Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD. ICP-332 achieved multiple efficacy endpoints in the China […]